Lim obtained her Hematopathology fellowship training at the National Cancer Institute after which she assumed a faculty position at the University of Toronto (1998-2000), the University of Utah (2000-2006), and the University of Michigan (2000-2015) before moving to the University of Pennsylvania in 2015. in Molecular Oncology from the University of Calgary and the National Cancer Institute Lab of Pathology jointly. from the University of Calgary and a Ph.D. Megan Lim i s the Director of the Joint Division of Hematopathology, Hospital of the University of Pennsylvania and the Children’s Hospital of Philadelphia in the Department of Pathology and Laboratory Medicine, Director of the Hematopathology Fellowship Program, Interim Director of the Clinical Flow Cytometry Laboratory, and the Director of the Lymphoma Biology Program at the Abramson Cancer Center. He has received the Cleveland Clinic Innovator Award and has been voted as one of the area’s Best Doctors by Cleveland Magazine.ĭr.
#Medical conferences 2016 hawaii october professional
He serves as an editorial board member of several journals, sits on national committees for several professional societies, and is a member of the Scientific Advisory Board for the Lymphoma Research Foundation. Hsi has authored over 250 peer-reviewed publications, two books, many book chapters, and 300 abstracts. He is a long-time member of the American Society of Clinical Pathology, College of American Pathologists, United States & Canadian Association of Pathologists, and Society for Hematopathology and frequently lectures at national and international meetings. In addition to his clinical and academic commitments, he is actively involved in ALLIANCE as Chair of the Pathology Committee as well as Vice-Chair of the Lymphoma Committee Translational Science. His research interests include pre-clinical therapeutics assessment and biomarkers in lymphoma and leukemia. He is an expert in the diagnosis and classification of hematologic malignancy with interests in immunophenotyping and molecular hematopathology. Eric Hsi i s Department Chair of Pathology at Wake Forest University School of Medicine. Hasserjian is strongly committed to education in hematopathology and has lectured on the diagnosis of leukemias, other bone marrow disorders, and lymphomas at numerous courses and international pathology meetings across the Americas, Europe, and Asia.ĭr. He is a Senior Reviewer and author of multiple chapters of the Revised 4th Edition (2016) WHO Classification of Myeloid Neoplasms and is an author of the American Society of Hematology/College of American Pathology Guidelines for the Initial Diagnostic Workup of Acute Leukemia. Hasserjian is an author of over 150 peer-reviewed publications, reviews, and chapters. Specific research has focused on the pathologic risk-stratification of myelodysplastic syndromes, acute myeloid leukemia, therapy-related myeloid neoplasms, and erythroid leukemias. His research interests are in the discovery of pathologic and genetic features associated with the biological behavior of myeloid and lymphoid neoplasms. He was a co-organizer of the 2017 Society for Hematopathology/European Association for Hematopathology Annual Workshop. Hasserjian has served on the Education Committee of the United States and Canadian Academy of Pathology and the Executive Committee of the Society for Hematopathology. He serves as a consultant to the pathology community for difficult cases and is recognized internationally for his diagnostic hematopathology expertise. His clinical expertise is in the diagnosis of lymphomas and bone marrow disorders, in particular leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Hasserjian received his MD from Harvard in 1990 and trained in Anatomic Pathology and Hematopathology at Brigham and Women’s Hospital. Robert Hasserjian i s a Professor of Pathology at Harvard Medical School and a Hematopathologist at Massachusetts General Hospital, where he is Director of the Hematopathology Fellowship.